6/24/2025

Repligen’s first quarter results for 2025 saw revenue and adjusted profits exceed Wall Street expectations, but the market reacted negatively, reflecting investor caution. Management attributed growth to strong demand across its protein, chromatography, and analytics product lines, as well as robust order momentum in biopharma manufacturing. CEO Olivier Loeillot highlighted that "orders were up high teens year on year with all franchises growing double digits," and noted particularly strong perf

Source: Yahoo

6/10/2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Source: Yahoo

6/8/2025

Repligen has struggled with falling sales, margin pressure, and a weakened growth outlook, making its premium valuation hard to justify. Learn why RGEN stock is a hold.

Source: SeekingAlpha

6/5/2025

The United States market has experienced a steady climb, rising 1.4% in the last week and showing a robust 12% increase over the past year, with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amidst positive market momentum.

Source: Yahoo

6/5/2025

Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.

Source: Yahoo

6/4/2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.

Source: Yahoo

6/3/2025

Presenter SpeechMatthew Stanton [Audio Gap] I will turn it over to Olivier. Thank you.Presenter SpeechOlivier Loeillot Thank you so much, Matt. Good afternoon, everybody. And he pronos my name

Source: Finnhub

6/2/2025

Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.

Source: Yahoo

6/2/2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Source: Yahoo

5/29/2025

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

5/28/2025

The Baird Small/Mid Cap Growth portfolio decreased -10.6% in the first quarter, net of fees, compared to the -10.8% decline in our primary benchmark, the Russell 2500 Growth Index.

Source: SeekingAlpha

5/27/2025

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Commu

Source: Yahoo

5/26/2025

Source: SeekingAlpha

5/22/2025

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repli

Source: Yahoo

5/20/2025

Presenter SpeechConor Noel McNamara Okay. Good afternoon, and welcome to the RBC Capital Markets 2025 Global Healthcare Conference. I'm Conor McNamara, the Life Science Tools and Diagnostics

Source: Finnhub

5/19/2025

Investor Presentation May 2025 ...

Source: Finnhub

5/16/2025

Source: SeekingAlpha

5/12/2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.

Source: Yahoo

5/9/2025

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

Source: Yahoo

5/7/2025

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-

Source: Yahoo